CBRX News Alert Columbia Laboratories (CBRX) 5.46 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Columbia Laboratories (CBRX) 5.46 $CBRX

Molecular Profiles To Launch US Strategic Alliance At AAPS
PR Newswire - Thu Oct 30, 7:30AM CDT
Molecular Profiles Ltd., a subsidiary of Columbia Laboratories, Inc., (Nasdaq: CBRX) and Maryland-based Xceleron have announced a collaboration to assist drug developers with improved efficiency during clinical development that will be launched at AAPS in San Diego next week.
CBRX: 5.46 (+0.10)

Columbia Laboratories achieves higher Q3 2014 net income of USD3.7m
M2 - Wed Oct 29, 4:48AM CDT
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) on Tuesday reported that its net income was USD3.7m, or USD0.34 per diluted share, for the three month periods ended 30 September 2014.
CBRX: 5.46 (+0.10)

Columbia Laboratories' (CBRX) CEO Frank Condella on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Oct 28, 1:39PM CDT

CBRX: 5.46 (+0.10)

Columbia Laboratories raises guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 1:05PM CDT

CBRX: 5.46 (+0.10)

Columbia Laboratories EPS of $0.34
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 6:18AM CDT

CBRX: 5.46 (+0.10)

Columbia Laboratories Reports Third Quarter 2014 Financial Results
PR Newswire - Tue Oct 28, 6:00AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company" today announced financial results for the three and nine-month periods ended September 30, 2014.
CBRX: 5.46 (+0.10)

OTC Daily Alert Stock Watch - Columbia Laboratories, Inc. (NASDAQ: CBRX)
WorldStockWire - Sun Oct 19, 12:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
CBRX: 5.46 (+0.10)

Columbia Labs reports on October 28
Seeking Alpha - at Seeking Alpha - Wed Oct 15, 9:17AM CDT

CBRX: 5.46 (+0.10)

Columbia Laboratories to Discuss Third Quarter 2014 Financial Results on October 28th Conference Call
PR Newswire - Tue Oct 14, 11:51AM CDT
The management team at Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on October 28th, 2014, to discuss financial results for the third quarter ended September 30, 2014. The call details are as follows:
CBRX: 5.46 (+0.10)

Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI
PR Newswire - Wed Oct 01, 7:30AM CDT
Columbia Laboratories, Inc., (Nasdaq: CBRX) today announced that its subsidiary, Molecular Profiles Ltd., is set to unveil the ROADMAP to Clinical Trials platform at the annual CPhI/ICSE Worldwide event in Paris next week, which aims to support companies with the rapid development of both standard and complex drug products.
CBRX: 5.46 (+0.10)

Columbia Laboratories announces George O. Elston as its new CFO
M2 - Thu Sep 25, 7:30AM CDT
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) said on Wednesday that its board has appointed George O. Elston as its chief financial officer.
CBRX: 5.46 (+0.10)

Columbia Laboratories Announces Appointment of New Chief Financial Officer
PR Newswire - Wed Sep 24, 7:30AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company" , a provider of pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry, today announced that the Board has named George O. Elston, 50, as Chief Financial Officer, effective October 1. He succeeds Jonathan Lloyd Jones, who is stepping down from the role to pursue other opportunities.
CBRX: 5.46 (+0.10)

Columbia Laboratories Shares Up 6.3% Since SmarTrend's Buy Recommendation (CBRX)
Comtex SmarTrend(R) - Mon Sep 22, 5:22PM CDT
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 14 months, Columbia Laboratories has returned 6.31% as of today's recent price of $5.98.
CBRX: 5.46 (+0.10)

Columbia Laboratories to participate in the Rodman & Renshaw 16th Annual Global Investment Conference
PR Newswire - Wed Aug 27, 8:00AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company" , a provider of pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry, today announced that it will participate at the upcoming Rodman & Renshaw 16th Annual Global Investment Conference, to be held in New York. The Company will present at the conference at 11:15am on September 9, 2014 at the New York Palace Hotel.
CBRX: 5.46 (+0.10)

Columbia Laboratories reports divestiture of Legatrin's IP and technology to Lil' Drug Store Products for USD2.2m
M2 - Thu Aug 07, 7:13AM CDT
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) reported on Wednesday the sale of the Intellectual Property (IP) Rights and Technology related to Legatrin P.M to Lil' Drug Store Products following exercise of option from a previous agreement.
CBRX: 5.46 (+0.10)

Columbia Laboratories Announces Sale Of IP And Technology For Legatrin P.M. To Lil' Drug Store Products
PR Newswire - Wed Aug 06, 7:30AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced that Lil' Drug Store Products exercised its option to purchase the Intellectual Property Rights and Technology related to Legatrin P.M. Columbia licensed this product to Lil' Drug Store Products approximately fourteen years ago and has received annual royalties. Based on a predetermined formula, Columbia will receive approximately $2.2 million for the sale.
CBRX: 5.46 (+0.10)

Columbia Laboratories posts lower net income of USD0.2m for Q2 2014
M2 - Fri Aug 01, 8:16AM CDT
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) stated on Thursday its net income of USD0.2m, or USD0.01 per diluted share, for the three month period ended 30 June 2014.
CBRX: 5.46 (+0.10)

Columbia Laboratories' Subsidiary, Molecular Profiles, Strikes Alliance With Xenogesis
PR Newswire - Thu Jul 31, 6:00AM CDT
Columbia Laboratories, Inc. (NASDAQ: CBRX) today announced that its subsidiary, Molecular Profiles Ltd., and XenoGesis Ltd., have announced a collaboration that will support pharmaceutical and biotech drug developers during the pre-clinical and formulation development stage. Molecular Profiles' pharmaceutical development services will be supported by XenoGesis' expertise in preclinical drug metabolism and pharmacokinetics (DMPK) to give clients a smarter route into formulation development and a better understanding of a compound's bioavailability. This strategic alliance will allow the Nottingham-based companies to help drug developers in the initial design and selection of compounds for key DMPK and ADME (absorption, distribution, metabolism and elimination) studies, as well as supporting lead candidates which have solubility issues during formulation development.
CBRX: 5.46 (+0.10)

Columbia Laboratories Reports Second Quarter 2014 Financial Results
PR Newswire - Thu Jul 31, 6:00AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company" today announced financial results for the three and six-month periods ended June 30, 2014.
MRK: 57.46 (+0.25), CBRX: 5.46 (+0.10)

Columbia Laboratories Up 11.8% Since SmarTrend Uptrend Call (CBRX)
Comtex SmarTrend(R) - Fri Jul 25, 9:59AM CDT
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 12 months, Columbia Laboratories has returned 11.82% as of today's recent price of $6.29.
CBRX: 5.46 (+0.10)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pinnacol’s Community Work Earns Denver Chamber Recognition

Updated Category News Views 67

A workers’ comp insurer usually becomes visible on somebody’s worst day; Pinnacol Assurance is being recognized for the work it keeps doing around those days. The Denver Metro Chamber of Commerce has given the Colorado-based, member-owned carrier its 2026 Business Impact Award for Corporate Social Responsibility. Awards can be cheap applause, frankly. This one...

Continue Reading
CVRx Lawsuit Puts a Hard Date on Investor Decisions

Updated Category News Views 65

One ugly filing after the bell can vaporize years of shareholder confidence, and CVRx just supplied the painful exhibit. On August 7, 2026, shares of CVRx fell $3.55, or 59.76%, to close at $2.39 after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That is not a routine bad quarter. It is the sort of disclosure...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 23

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 99

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 104

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
Protein Now! Gains Clinician Attention, With Caveats

Updated Category News Views 91

A Small Bottle Has Drawn a Crowd Protein powder tubs have been cluttering kitchens for years; a 3.38-fluid-ounce shot is a cleaner answer to the same daily hassle. NutraBio Labs says more than 800 physicians, nurse practitioners, and physician associates had added PROTEIN NOW! to their individual FrontrowMD patient pages as of November 2026. That earned the product a...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 14

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Africa Tech Festival Puts Trust Ahead of AI Hype Cycle

Updated Category News Views 75

Fifteen thousand people can fill a convention centre, but they cannot magically deliver a package, fund a small business, or repair harm from a bad automated decision. That rather useful dose of reality ran through the final day of Africa Tech Festival 2026 in Cape Town. The 29th edition drew more than 15,000 delegates across three days, and the strongest message was not...

Continue Reading
Epiroc Takes Live Remote Drilling to CES 2027 Stage

Updated Category News Views 48

A drill rig chewing through Virginia rock from a Las Vegas convention booth is either a serious industrial-tech moment or an expensive magic trick. At CES 2027, Epiroc intends to make the distinction painfully clear. From January 6 through 9, the Stockholm-based mining-equipment company and Luck Stone will connect Booth 7031 in the LVCC West Hall to a working quarry in...

Continue Reading
Healthcare's Prevention Puzzle Needs Better Incentives

Updated Category News Views 113

When Savings Belong to the Next Plan A patient changing insurance plans can turn prevention into nobody’s asset. That is the uncomfortable little engine inside Russell Greenfield’s recent argument: an insurer may pay today for a program that helps prevent chronic illness, only to watch the eventual savings land with another plan after the member moves on. The person...

Continue Reading

Top 5 Most Recently Viewed Articles

ICG Enterprise Trust plc Announces Share Repurchase Details

Updated Category News Views 159

ICG Enterprise Trust plc Share Buyback Announcement ICG Enterprise Trust plc (the “Company”) The Company has announced a recent development regarding its share buyback initiative. On a significant date, it repurchased 15,000 of its own shares aimed to be held as treasury shares, with each share valued at an average price of 1450 pence. Details of the Transaction...

Continue Reading
Converge Technology Solutions Shares Third Quarter 2024 Insights

Updated Category News Views 217

Converge Technology Solutions Announces Preliminary Q3 Results Converge Technology Solutions Corp. (CTS) has released its preliminary unaudited financial results for the third quarter of 2024. The company is committed to delivering insightful updates to its stakeholders as part of its transparency approach. The company stated that all figures are presented in Canadian...

Continue Reading
Discovery Silver Corp. Unveils 2023 ESG Report

Updated Category News Views 104

Discovery Silver Corp. Releases 2023 ESG Report Key Highlights: Earned Quality Environmental Certification from the Mexican Government Recognized as a Socially Responsible Enterprise by the Mexican Center for Philanthropy Achieved Great Place to Work Certification Discovery Silver Corp. (TSX: DSV, OTCQX: DSVSF) is excited to announce the publication of its 2023...

Continue Reading
Final Call for Subscription in IDEX Biometrics Offering Today

Updated Category News Views 152

Important Subscription Period Details for IDEX Biometrics Today marks a significant turning point for IDEX Biometrics ASA as the subscription period for their subsequent offering of shares closes. The company previously announced that they aim to issue up to 600 million new shares at a remarkable subscription price of NOK 0.01 per share. This offering, essential for...

Continue Reading
Dundee Corporation Strengthens Position in Greenheart Gold Inc.

Updated Category News Views 33

Overview of Recent Acquisition Dundee Corporation (TSX: DC.A) has announced that its wholly-owned subsidiary, Dundee Resources Limited, recently acquired 2,000,000 common shares of Greenheart Gold Inc. (TSXV: GHRT) at a price of C$0.50 per share, totaling an investment of C$1,000,000. This acquisition is part of the Issuer's bought deal private placement and signifies...

Continue Reading